Abstract
Belimumab (Benlysta®), a human immunoglobulin (Ig) G1λ monoclonal antibody targeting B lymphocyte stimulator, is effective as an add-on to standard therapy in patients with active, autoantibody-positive systemic lupus erythematosus (SLE). Belimumab was first approved in 2011 as an intravenous (IV) treatment for adults with SLE. Since then, a subcutaneous formulation of belimumab has been approved in adults and, most recently, IV belimumab has been approved in children aged ≥ 5 years. In adults with active, autoantibody-positive SLE, add-on belimumab improves overall disease activity and flare rates. Belimumab appears to have a steroid-sparing effect and disease control is maintained over long-term use. The clinical benefits of IV belimumab in children with SLE are consistent with those in adults. Belimumab is generally well tolerated in both adults and children.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
